|
Dec 22
|
Ionis, Astrazeneca win FDA approval of competitor to Alnylam drug
|
|
Dec 19
|
13 Most Promising Healthcare Stocks According to Analysts
|
|
Dec 13
|
Alnylam Highlights Significant Progress with Platform Innovation and Clinical Pipeline at R&D Day
|
|
Dec 6
|
Alnylam to Webcast Virtual R&D Day
|
|
Nov 30
|
Alnylam Ranks #1 on Boston Globe’s Top Places to Work List for 2023
|
|
Nov 8
|
Wall Street Analysts Think Alnylam (ALNY) Could Surge 35.08%: Read This Before Placing a Bet
|
|
Nov 7
|
Alnylam to Webcast Presentations at Upcoming November Investor Conferences
|
|
Nov 4
|
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q3 2023 Earnings Call Transcript
|
|
Nov 3
|
Alnylam (ALNY) Swings to Earnings in Q3 on Collaboration Revenues
|
|
Nov 3
|
Agios (AGIO) Reports Narrower-Than-Expected Q3 Loss, Lags Sales
|
|
Nov 2
|
Alnylam Pharmaceuticals Inc (ALNY) Reports 35% YoY Growth in Q3 2023 Net Product Revenues
|
|
Nov 2
|
Alnylam (ALNY) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
|
|
Nov 2
|
Alnylam Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Period Activity
|
|
Sep 8
|
Biotech Stock Roundup: MRNA's Vaccine Update, AMGN & HZNP Clear FTC Lawsuit & More
|
|
Sep 8
|
Alnylam's (ALNY) Zilebesiran Meets Goals in Mid-Stage Study
|
|
Sep 7
|
Why Is Qiagen (QGEN) Down 4.8% Since Last Earnings Report?
|
|
Sep 7
|
UPDATE 2-Alnylam's gene-silencing drug cuts blood pressure in mid-stage trial
|
|
Sep 7
|
Alnylam Reports Positive Topline Results from KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development to Treat Hypertension in Patients at High Cardiovascular Risk
|
|
Sep 6
|
CRISPR Therapeutics AG (CRSP) Down 5.3% Since Last Earnings Report: Can It Rebound?
|
|
Sep 6
|
First Set of Recommendations Advocating for the Holistic Care of People Living with hATTR Amyloidosis Developed by International Panel of Patient Advocates and Healthcare Professionals
|